Author

D. Schadendorf

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Assay:scRNA-seq· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

A. Roesch· 2 shared A. Zaremba· 2 shared B. Schilling· 2 shared S. Horn· 2 shared A. D. Amin· 1 shared A. Gangaev· 1 shared A. Giobbie-Hurder· 1 shared A. Paschen· 1 shared

Activity by Year

2020-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Roesch

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

G. Tarantino, C. A. Ricker, A. Wang, W. Ge, T. J. Aprati, A. Y. Huang, S. Madha, J. Chen, Y. Shi, M. Glettig, D. T. Frederick, S. Freeman, M. M. Holovatska, M. P. Manos, L. Zimmer, , D. Liu

This study identifies genomic heterogeneity and ploidy as markers of intrinsic resistance to PD-1 blockade in metastatic melanoma, with a decision tree model predicting resistance with high confidence.

Science Advances · Nov 29, 2024Peer-reviewedCancer Biology

TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities

C. K. Kuhn, J. Meister, S. Kreft, M. Stiller, S.-H. Puppel, A. Zaremba, B. Scheffler, V. Ullrich, T. Schöneberg, D. Schadendorf, S. Horn

This study investigates TERT expression in cancer, finding its association with metastasis, exhausted CD4+ T cells in melanoma, and DNA repair across multiple cancer types.

bioRxiv · Jan 25, 2023 · PreprintCancer Biology

The CD58:CD2 axis is co-regulated with PD-L1 via CMTM6 and governs anti-tumor immunity

P. Ho, J. C. Melms, M. Rogava, C. J. Frangieh, S. B. Shah, Z. Walsh, O. Kyrysyuk, A. D. Amin, L. Caprio, B. T. Fullerton, R. Soni, C. R. Ager, J. Biermann, Y. Wang, M. Mu, , B. Izar

The paper identifies the CD58:CD2 axis as co-regulated with PD-L1 via CMTM6 and shows its role in anti-tumor immunity, proposing therapeutic strategies to enhance immunotherapy.

bioRxiv · Mar 21, 2022 · PreprintCancer Biology

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

A. Gangaev, E. A. Rozeman, M. W. Rohaan, D. Philips, S. Patiwael, J. H. van den Berg, A. Ribas, D. Schadendorf, B. Schilling, T. Shumacher, C. Blank, J. B. A. G. Haanen, P. Kvistborg

The paper shows PD-1 blockade in melanoma patients does not increase the breadth or magnitude of melanoma-reactive CD8 T cells in peripheral blood, suggesting PD-1 acts mainly at the tumor site.

bioRxiv · Dec 15, 2020Immunology

Persister state-directed transitioning and vulnerability in melanoma

H. Chauvistre, B. Shannan, S. M. Daignault, R. J. Ju, D. Picard, S. Egetemaier, R. Varaljai, A. Sechi, F. Kaschani, O. Keminer, S. J. Stehbens, Q. Liu, X. Yin, K. Jeyakumar, F. C. E. Vogel, , A. Roesch

This study identifies a compound that induces a persister state in melanoma cells, promoting differentiation and sensitizing them to a prodrug, offering a dual-target strategy for treatment.

bioRxiv · Apr 1, 2020Cancer Biology